NEW YORK, June 20, 2017 /PRNewswire/ --
If you want a stock review on OPK, PTIE, TRVN, or DVAX then come over to http://dailystocktracker.com/register/ and sign up for your free customized reports today. This morning, DailyStockTracker.com turns investors' attention to Opko Health Inc. (NASDAQ: OPK), Pain Therapeutics Inc. (NASDAQ: PTIE), Trevena Inc. (NASDAQ: TRVN), and Dynavax Technologies Corp. (NASDAQ: DVAX). According to the 31st annual EY report, Beyond borders: staying the course, global Biotech companies continue to invest in new treatments despite a pullback from capital markets in the US and the EU, lower valuations, and increased pressure from payers. Daily Stock Tracker published free research reports on these stocks today at:
Miami, Florida headquartered Opko Health Inc.'s shares gained 0.92%, closing Monday's trading session at $6.59. The stock recorded a trading volume of 4.44 million shares, which was above its three months average volume of 4.06 million shares. Shares of the Company are trading 6.01% below their 50-day moving average. Additionally, shares of Opko Health, which engages in the diagnostics and pharmaceuticals business in the US, Ireland, Chile, Spain, Israel, and Mexico, have a Relative Strength Index (RSI) of 48.83.
On June 07th, 2017, Opko Health announced that GeneDx, a business unit of the Company's BioReference Laboratories division, extended its relationship with the University of California Health (UC Health) for genetic, genomic, and molecular testing services. By having access to the latest in next generation genetics and molecular oncology resources, both internally and externally, UC Health remains at the forefront of precision medicine. See our free and comprehensive research report on OPK at:
On Monday, shares in Austin, Texas-based Pain Therapeutics Inc. recorded a trading volume of 21,698 shares. The stock rose 2.44%, ending the day at $4.20. The Company's shares have advanced 5.23% on an YTD basis. The stock is trading below its 50-day moving average by 12.18%. Furthermore, shares of Pain Therapeutics, which develops drugs for treating nervous system in the US, have an RSI of 49.33.
On June 05th, 2017, Pain Therapeutics announced that the National Institutes of Health (NIH) has awarded the Company a $1.7-million research grant to study PTI-125, a drug candidate in Alzheimer's disease. This NIH research grant will enable the Company to begin testing PTI-125 in human subjects. An Investigational New Drug application for PTI-125 is on-track for submission to the US FDA in Q3 2017. PTIE free research report is just a click away at:
King of Prussia, Pennsylvania headquartered Trevena Inc.'s stock finished the day 1.63% higher at $2.49. A total volume of 1.02 million shares was traded, which was above their three months average volume of 625,680 shares. Shares of the Company are trading below their 50-day moving average by 17.38%. Additionally, shares of Trevena, which develops various therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions, have an RSI of 38.11.
On June 02nd, 2017, Trevena announced that it will be attending the JMP Securities Life Sciences Conference on June 21st, 2017, at 8:30 a.m. EDT in New York. Sign up for your complimentary report on TRVN at:
Shares in Berkeley, California headquartered Dynavax Technologies Corp. ended yesterday's session 5.73% higher at $8.30. The stock recorded a trading volume of 2.44 million shares, which was above its three months average volume of 1.25 million shares. The Company's shares have surged 48.21% in the last one month, 38.33% over the previous three months, and 110.13% since the start of this year. The stock is trading 40.06% and 24.06% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Dynavax Technologies, which focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation, have an RSI of 82.34.
On June 02nd, 2017, Dynavax Technologies announced the presentation of findings in patients with metastatic melanoma in the dose escalation phase of an ongoing Phase-1b/2 study investigating SD-101, the Company's intratumoral TLR9 agonist, in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy developed by Merck, known as MSD outside the US and Canada. SD-101 in combination with KEYTRUDA generally was well tolerated. No dose-limiting toxicities of the combination were observed in any dose cohort, and a maximum tolerated dose was not identified. Sign up and read the free research report on DVAX at:
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA